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Abstract
Background: Experimental studies suggest that pre-stroke statin treatment has a dual effect of neuroprotection
during ischemia and neurorestoration after ischemic injury. The aim of this study was to evaluate the effect of
pre-stroke statin use on initial stroke severity and early clinical outcome.
Methods: We used a prospective database enrolling patients with acute ischemic stroke from 12 hospitals in Korea
between April 2008 and January 2012. Primary endpoint was the initial stroke severity as measured by the National
Institutes of Health Stroke Scale (NIHSS) score. Secondary endpoints were good outcome (modified Rankin Scale
[mRS], 0–2) and overall mRS distribution at discharge. Multivariable regression model and propensity score (PS)
matching were used for statistical analyses.
Results: Among the 8340 patients included in this study, 964 patients (11.6 %) were pre-stroke statin users. The
initial NIHSS score (mean [95 % CI]) was lower among pre-stroke statin users vs. non-users in multivariable analysis
(5.7 [5.2–6.3] versus 6.4 [5.9–6.9], p = 0.002) and PS analysis (5.2 [4.7–5.7] versus 5.7 [5.4–6.0], p = 0.043). Pre-stroke
statin use was associated with increased achievement of mRS 0–2 outcome (multivariable analysis: OR [95 % CI],
1.55 [1.25–1.92], p < 0.001; PS matching: OR [95 % CI], 1.47 [1.16-1.88]; p = 0.002) and favorable shift on the overall
mRS distribution (multivariable analysis: OR [95 % CI], 1.29 [1.12-1.51], p = 0.001; PS matching: OR [95 % CI], 1.31
[1.11-1.54]; p = 0.001).
Conclusions: Pre-stroke statin use was independently associated with lesser stroke severity at presentation and
better early functional recovery in patients with acute ischemic stroke.
Keywords: Acute stroke, Statins, Outcomes
Background
Statin use before cerebral ischemia was associated with a
smaller infarction volume or more collaterals in patients
with an acute large cerebral artery occlusion [1, 2],
which are in accord with experimental statin studies
showing a neuroprotective effect during ischemia and a
neurorestorative effect after ischemic injury [3–9]. How-
ever, the effects of pre-stroke statin use on clinical stroke
severity and functional outcomes have been inconsistent
[2, 10–24]. Pre-stroke statin use was independently associ-
ated with milder stroke severity in limited studies [15, 21].
Improved functional outcomes in patients with pre-stroke
statin use have been demonstrated in multiple studies
[10–12, 15, 16, 18, 19, 24], but it is not clear whether the
improved functional outcome was attributed to a neuro-
protective effect leading to milder stroke severity at pres-
entation or to a neurorestorative effect after ischemia.
Small sample sizes, selection bias, or limited availability of
detailed information in human clinical studies are likely to
result in these conflicting results. We tested a hypothesis
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that whether pre-stroke statin use is associated with initial
stroke severity as well as early stroke recovery, by analyz-
ing a large dataset from a multicenter registry that pro-




We used data from the Clinical Research Center for
Stroke-5 (CRCS-5) registry, which is a prospective regis-
try of consecutive patients with acute ischemic stroke or
transient ischemic attack (TIA) admitted to 12 academic
centers in Korea (http://www.stroke-crc.or.kr). The
CRCS-5 registry was launched in April 2008 to facilitate
multicenter collaborative clinical stroke research in
Korea and to implement clinical practice guidelines for
stroke [25], and was approved by the Institutional
Review Boards (IRBs) of all participating centers (Jeju
National University Hospital, Seoul Medical Center, Ilsan
Paik Hospital, Eulji General Hospital, Soonchunhyang
University Hospital, Eulji University Hospital, Yeungnam
University Hospital, Chonnam National University
Hospital, Hallym University Sacred Heart Hospital,
Dong-A University, Seoul National University Bundang
Hospital, and Dongguk University Ilsan Hospital). The
informed consent from individual patients or their le-
gally authorized representatives was waived by the rele-
vant IRBs because the registry aimed to monitor and
improve the quality of stroke care and a computer-
assisted de-identification system ensured the anonymity of
individual patients during data collection. The Steering
Committee of the CRCS-5 Registry approved the access
and analysis of the database.
For this study, we analyzed the CRCS-5 dataset of pa-
tients hospitalized with acute ischemic stroke between
April 1, 2008 and January 31, 2012. Inclusion criteria
were (1) age ≥18 years, and (2) arrival at the emergency
room (ER) within 48 h from symptom onset. Exclusion
criteria were (1) pre-stroke disability as measured by a
modified Rankin Scale (mRS) score of >1; (2) unavail-
ability of discharge mRS; (3) TIA patients without rele-
vant neuroimaging findings; (4) unavailability of
ischemic stroke subtype of Trial of Org 10172 in Acute
Stroke Treatment (TOAST) classification; and (5) pa-
tients who were treated with thrombolytic therapy. For
patients treated with thrombolytic therapy, the success
of thrombolytic therapy would predominantly affect the
early post-stroke functional outcome. Therefore, we ex-
cluded those patients from the primary analysis cohort.
Data of patients treated with thrombolytic therapy and
all patients, including those treated with and not treated
with thrombolytic therapy, were additionally analyzed
and presented in the supporting information.
Data collection
Using a web-based registry which provided a pre-defined
standardized coding system, we prospectively and sys-
tematically captured the following data for each patient:
(1) demographics of age, sex, height, weight, body mass
index (kg/m2), and systolic and diastolic blood pressure
at admission; (2) laboratory findings of glucose at admis-
sion, fasting total cholesterol, and fasting LDL cholesterol;
(3) vascular risk factors of hypertension, diabetes mellitus,
hyperlipidemia, smoking, atrial fibrillation, and prior his-
tory of stroke and coronary artery disease; (4) use of medi-
cations prior to the index stroke including antiplatelet
agents, medications for hypertension, diabetes mellitus,
and hyperlipidemia including statins; and (5) characteris-
tics of the index stroke including pre-stroke and discharge
functional disability measured by mRS score, initial stroke
severity measured by the National Institutes of Health
Stroke Scale (NIHSS) score, and use of thrombolytic
therapy. Ischemic stroke was classified as large-artery
atherosclerosis (LAA), small-vessel occlusion (SVO),
cardioembolism (CE), stroke of undetermined etiology
(UDE) or stroke of other determined etiology (ODE)
according to the TOAST criteria [26]. Symptomatic
stenosis or occlusion (SYSO) of the major arteries was
assessed using computed tomography angiography, mag-
netic resonance angiography, or conventional catheter
angiography. For intracranial arteries, it was defined as
more than 50 % stenosis of the artery compared with
proximal or distal normal segment [27]. In this study,
pre-stroke statin use was defined as taking statin at the
time of the index ischemic stroke. Participating investi-
gators and research nurses were trained and obtained
certification for the NIHSS and mRS scoring using a
web-based certification program provided in the CRCS
website (http://www.stroke-crc.or.kr).
Outcome measurement
The primary outcome was the initial stroke severity as
measured by the NIHSS score. The secondary outcome
was early post-stroke functional outcomes as assessed by
mRS score at discharge.
Statistical analysis
For missing data with more than 10 % of total observa-
tion was excluded from the analysis. We used simple im-
putation with median value for variables with missing
data less than 10 % of total observation. Baseline charac-
teristics between pre-stroke statin users and non-users
were compared with Student t-test for continuous vari-
ables with a normal distribution, Wilcoxon rank-sum test
for continuous variables without a normal distribution, or
the chi-square test for categorical variables. When com-
paring the primary endpoint of the initial NIHSS score be-
tween the two groups, the Wilcoxon rank-sum test was
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used for a univariable analysis and an analysis of covari-
ance (ANCOVA) test was used to adjust for covariates,
which showed a p-value <0.25 on the comparisons of
baseline characteristics between the two groups. Add-
itionally, we compared the proportion of mild stroke
(ie, NIHSS score 0 to 4) between two groups as a di-
chotomized outcome. To further explore a differential
effect of prior statin use on initial stroke severity by is-
chemic stroke subtypes, we compared the initial NIHSS
scores between the two groups stratified by the TOAST
classification. For the stratified analysis, we combined
UDE and ODE subtypes. Multivariable analyses accord-
ing to individual TOAST subtypes included covariates
that were selected for the adjusted analysis of the pri-
mary endpoint. However, the variable of the TOAST
subtype was excluded.
When analyzing mRS scores at discharge, we com-
pared the proportion of mRS scores of 0–2 and the over-
all distribution of mRS scores between the two groups.
For the analysis of the overall mRS distribution, we
employed 6 levels by collapsing mRS 5 and mRS 6 into a
single level of extreme disability or death [28]. The odds
ratio (OR) and 95 % confidence interval (CI) were calcu-
lated to estimate the probabilities of achieving a dis-
charge mRS 0–2 outcome and a favorable shifting of one
level on the mRS score for statin users. To adjust covari-
ates, multiple logistic regression was conducted for the
dichotomized mRS outcome and ordinal logistic regres-
sion analysis for the overall mRS distribution. Covariates
were adjusted in the same way as for the primary end-
point, and the initial NIHSS score and statin use during
hospitalization were additionally included. We used the
following formula to calculate number needed to treat
(NNT) using OR and control event rate (CER) [29].
NNT ¼ CER OR−1ð Þ þ 1=CER OR−1ð Þ  1−CERð Þ½ 
Because neurological status of stroke patients tends to
change during acute phase, we performed stratified ana-
lysis by median onset to arrival time to investigate whether
there is a difference of prestroke statin effect according to
onset to arrival time.
In addition to multivariable analyses, we conducted
propensity score (PS) analyses to reduce the bias due to
confounding variables. To obtain PS, we used logistic re-
gression, in which pre-stroke statin use was employed as
a dependent variable. The model included all patient
pretreatment characteristics with respect to prior statin
use. After obtaining PS, statin users were 1-to-n (n ranged
from one to four) matched to non-users within 0.2 × SD of
the logit of the propensity score. Standardized differences
of covariates were used to assess baseline imbalances be-
tween the two groups after PS matching. Using the final PS
matched dataset, outcome analysis was performed with the
generalized estimation equation method. For covariates
with more than 0.1 standardized differences were further
adjusted on the matched analysis. In addition, stratification
by deciles of the PS was used as a sensitivity analysis. In all
analyses, a p-value <0.05 was considered statistically signifi-
cant. SAS computer software (Version9.3, SAS Institute,
Cary, NC, USA) was used for the statistical analyses.
Results
Study population
Of the 14,746 patients with acute ischemic stroke or TIA
enrolled in the CRCS-5 registry between April 1, 2008 and
January 31, 2012, we excluded 6406 patients in the fol-
lowing order: (1) 12 patients <18 years old; (2) 3310 pa-
tients arriving at the ER beyond 48 h from symptom
onset; (3) 1255 patients with a pre-stroke mRS score > 1;
(4) 15 patients without documentation of discharge mRS
score; (5) 170 patients of TIA without relevant acute is-
chemic lesions on neuroimaging; (6) 68 patients without
documentation of the TOAST classification; and (7) 1576
patients treated with intravenous or intra-arterial thromb-
olysis (Additional file 1: Figure S1).
The study population of the current analysis included
8340 patients. The mean age was 66.8 years (standard
deviation [SD], 12.7), and 59.6 % were men. The median
length of hospitalization was 8 days (interquartile range
[IQR], 6–13). The median NIHSS score at presentation
was 3 (IQR, 2–7). LAA (36.4 %) was the most common
ischemic stroke subtype, followed by SVO (23.5 %) and
CE (20.5 %). Other baseline characteristics are presented
in Table 1. Missing values were found on seven variables,
which ranged from 0.1 % to 2.2 % of the total observa-
tions (Additional file 1: Table S1).
Of the 8340 patients, 964 (11.6 %) were taking statins
at the time of the index stroke onset. Compared with
non-users, pre-stroke statin users were more likely to be
older and women, to have a pre-stroke disability of mRS
1, a history of hypertension, diabetes mellitus, hyperlip-
idemia, atrial fibrillation, coronary artery disease, and
prior stroke, and to have already been on antiplatelet
agents, angiotensin-receptor blockers (ARBs) or angio-
tensin converting enzyme inhibitors (ACEIs), beta-
blockers, diuretics, or calcium channel blockers (CCBs).
However, they had lower fasting total and LDL choles-
terol levels. The distribution of TOAST classification
also differed between the two groups. After PS matching,
the baseline characteristics did not differ significantly be-
tween the pre-stroke statin users and non-users (Table 1).
During hospitalization, 6258 patients (75.0 %) received
statin treatment, and 123 patients (12.8 %) of 964 pre-
stroke statin users did not receive statins. The reasons
for the statin withdrawal were not documented.
For patients treated with thrombolytic therapy and all
patients including those treated with and not treated with
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Table 1 Demographic and clinical characteristics of statin users and non-users
Before PS matching After PS matching
Statin users (n = 964) Non-users (n = 7376) P-value* Statin users (n = 618) Non-users (n = 1585) P-value**
Demographic
Mean age (SD), years 68.3 (10.6) 66.6 (12.9) <0.001 67.9 (10.9) 67.4 (11.9) 0.91
Male sex, n(%) 539 (55.9) 4433 (60.1) 0.013 345 (55.8) 891 (56.2) 0.99
Mean BMI (SD), kg/m2 24.1 (3.3) 23.6 (3.7) <0.001 23.9 (3.3) 23.8 (3.4) 0.99
Pre-stroke mRS, n(%) <0.001 0.68
0 834 (86.5) 6909 (93.7) 552 (89.3) 1458 (92.0)
1 130 (13.5) 467 (6.3) 66 (10.7) 127 (8.0)
Risk factors, n(%)
Hypertension 800 (83.0) 4765 (64.6) <0.001 482 (78.0) 1200 (75.7) 0.89
DM 458 (47.5) 2250 (30.5) <0.001 269 (43.5) 643 (40.6) 0.90
Hyperlipidemia 807 (83.7) 1771 (24.0) <0.001 461 (74.6) 1007 (63.5) 0.74
Smoking 344 (35.7) 3068 (41.6) <0.001 219 (35.4) 575 (36.3) 0.92
Atrial fibrillation 210 (21.8) 1307 (17.7) 0.002 133 (21.5) 305 (19.2) 0.76
History of stroke 345 (35.8) 1153 (15.6) <0.001 186 (30.1) 400 (25.2) 0.80
History of CAD 147 (15.3) 272 (3.7) <0.001 58 (9.4) 135 (8.5) 0.59
Lab, mean(SD)
SBP, mmHg 148.5 (26.9) 149.2 (27.4) 0.46 148.6 (26.1) 149.4 (28.0) 0.89
DBP, mmHg 84.2 (15.0) 87.0 (15.6) <0.001 85.5 (15.0) 85.8 (16.3) 0.98
Hemoglobin 13.4 (1.9) 13.8 (1.9) <0.001 13.6 (1.9) 13.6 (1.9) 0.56
Admission glucose, mg/dL 124.5 (51.1) 123.4 (52.4) 0.38 126.7 (51.9) 126.6 (52.8) 0.81
Total cholesterol, mg/dL 164.0 (42.0) 185.3 (40.8) <0.001 173.8 (43.3) 180.1 (42.6) 0.67
LDL cholesterol, mg/dL 93.6 (33.3) 113.4 (35.4) <0.001 101.6 (34.8) 106.8 (37.3) 0.67
Stroke characteristics
Median onset to arrival time
(IQR), hours
7.0 (2.5 - 19.5) 7.7 (3.0 - 20.0) 0.040 7.1 (2.5 - 19.9) 7.4 (2.8 - 19.8) 0.99
Stroke subtype, n(%) 0.98
Large artery atherosclerosis 361 (37.5) 2678 (36.3) <0.001 226 (36.6) 597 (37.7)
Small vessel occlusion 168 (17.4) 1790 (24.3) <0.001 116 (18.8) 334 (21.1)
Cardioembolism 234 (24.3) 1477 (20.0) <0.001 153 (24.8) 352 (22.2)
Others 201 (20.9) 1431 (19.4) <0.001 123 (19.9) 302 (19.1)
SYSO 409 (42.4) 3011 (40.8) 0.34 257 (41.6) 651 (41.1) 0.81
Pre-stroke medication, n(%)
Antiplatelet 671 (69.6) 1479 (20.1) <0.001 351 (56.8) 722 (45.6) 0.92
Anticoagulant 85 (8.8) 251 (3.4) <0.001 45 (7.3) 99 (6.2) 0.93
ARB or ACEI 435 (45.1) 1221 (16.6) <0.001 225 (36.4) 484 (30.5) 0.60
Beta-blocker 207 (21.5) 485 (6.6) <0.001 104 (16.8) 221 (13.9) 0.93
Diuretics 179 (18.6) 554 (7.5) <0.001 93 (15.0) 209 (13.2) 0.86
Calcium channel blocker 327 (33.9) 1124 (15.2) <0.001 170 (27.5) 404 (25.5) 0.85
SD Standard deviation, PS Propensity score, BMI Body mass index, mRS modified Rankin scale, DM Diabetes mellitus, CAD Coronary artery disease, SBP Systolic
blood pressure, DBP Diastolic blood pressure, IQR Interquartile range, SYSO, Symptomatic stenosis or occlusion, ARB Angiotensin-receptor blocker, ACEI Angiotensin
converting enzyme inhibitor
*P-values are calculated by Student's t-test, Pearson chi-square test, or Wilcoxon rank sum test as appropriate
**P-values are calculated by conditional logistic regression
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thrombolytic therapy, the baseline imbalances between
pre-stroke statin users and non-users were generally simi-
lar to those of patients not treated with thrombolytic ther-
apy (Additional file 1: Tables S2 and S3).
Primary outcome
The mean initial NIHSS score (95 % CI) was 4.6 (4.3–4.9)
among pre-stroke statin users and 5.4 (5.3–5.6) among
non-users. Accordingly, prior statin use was associated
with an average decrease of 0.8 points on the initial
NIHSS score (95 % CI, 0.5–1.2; p < 0.001) (Table 2). The
median initial NIHSS score did not differ numerically be-
tween the two groups, but the difference was statistically
significant because of the difference in the NIHSS score
distributions: 3 (IQR, 1–6) in pre-stroke statin users
versus 3 (IQR, 2–7) in non-users (unadjusted analysis,
p < 0.001) (Fig. 1A). After adjusting for age, sex, body
mass index, diastolic blood pressure, hemoglobin, total
cholesterol, LDL cholesterol, pre-stroke mRS, hyperten-
sion, diabetes mellitus, hyperlipidemia, atrial fibrilla-
tion, history of prior stroke and coronary heart disease,
smoking, prior use of an antiplatelet medication, ARB
or ACEI, beta-blocker, diuretic, CCB, onset-to-arrival,
and TOAST classification, the mean initial NIHSS score
remained significantly lower in statin users than in
non-users (5.7 [5.2–6.3] versus 6.4 [5.9–6.9]; ANCOVA
test, p = 0.002) (Table 2).
PS-matched sample included 619 pairs with 619 statin
users and 1585 non-users. The estimated logistic regres-
sion model and PS model equations were provided in the
online supplemental material (Additional file 1: Table S4).
Covariates including history of stroke, total choles-
terol, LDL cholesterol, and prior medications of any
antiplatelet and ARB or ACEI were further adjusted on
PS-matching analysis since they had more than 0.1
standardized differences between statin user and non-
users after the PS matching (Additional file 1: Figure
S2). The difference in the initial NIHSS scores between
pre-stroke statin users and non-users remained significant
in both the PS-matched cohort (5.2 [4.7–5.7] versus 5.7
[5.4–6.0], p = 0.043) (Fig. 1B) and the PS-stratification co-
hort (5.1 [4.7–5.6] versus 5.7 [5.6–5.9], p = 0.015) (Table 2).
The adjusted analysis using all patients data showed that
pre-stroke statin users compared to non-users were more
likely to present as mild stroke defined as NIHSS score
0–4. However, after PS matching, the findings were not
significant, but the direction favored pre-stroke statin
use (Additional file 1: Table S4).
Among TOAST subtypes, univariable analyses showed
that prior statin use was associated with lower initial NIHSS
scores in patients with LAA, SVO, and UDE or ODE, but
not in those with CE (Additional file 1: Figure S3). After
adjusting for covariates, the significance disappeared for
all TOAST subtypes, but in patients with LAA and SVO,
there were trends of lower initial NIHSS scores among
pre-stroke statin users (Additional file 1: Table S5).
When analyzing the 1576 patients who were treated with
thrombolytic therapy, the initial NIHSS score did not differ
between statin users and non-users (12.0 [6.5–17.0] vs 12.0
[6.0–17.0], unadjusted analysis) (Additional file 1: Table S2).
For 9916 patients, including non-thrombolysed and throm-
bolysed patients, the initial NIHSS score was lower in statin
users than in non-statin users (unadjusted mean [95 % CI],
Table 2 Comparisons of initial NIHSS scores between statin
users and non-users for unmatched and PS-matched cohorts
Statin users Non-users Difference P-value
Unmatched cohort
Unadjusted 4.6 (4.3–4.9) 5.4 (5.3–5.6) 0.8 (0.5–1.2) <0.001
Adjusteda 5.7 (5.2–6.3) 6.4 (5.9–6.9) 0.7 (0.2–1.1) 0.002
PS-matched cohort
PS-matchedb 5.2 (4.7–5.7) 5.7 (5.4–6.0) 0.5 (0.02–1.0) 0.043
PS-stratification,
decilesc
5.1 (4.7–5.6) 5.7 (5.6–5.9) 0.6 (0.1–1.1) 0.015
Values are mean (95 % CI) or least-square mean (95 % CI) as appropriate
aAdjusted for age, sex, body mass index, diastolic blood pressure, hemoglobin,
total cholesterol, LDL cholesterol, pre-stroke modified Rankin Scale score,
history of hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation,
history of stroke, history of coronary artery disease, smoking, prior antiplatelet
medication, anticoagulant, angiotensin receptor blocker or angiotensin
converting enzyme inhibitor, beta-blocker, diuretics, calcium-channel blocker,
TOAST classification, SYSO and onset to arrival time
bPS-matched sample included 618 pairs with one-to-n (n ranged from one to
four) matching: 618 statin users and 1585 non-users. Adjusted for
hyperlipidemia, history of stroke, total cholesterol, LDL cholesterol, prior
medications of any antiplatelet and ARB or ACEI, and SYSO
cAdjusted for SYSO
NIHSS National Institutes of Health Stroke Scale, PS Propensity score
Values presented are type III estimates
Fig. 1 Histogram showing initial NIHSS scores in statin users and
non-users of unmatched (n = 8340) (a) and PS-matched cohort
(n = 2203) (b)
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5.9 [5.5–6.3] vs 6.5 [6.3–6.6], p < 0.001; adjusted mean 7.2
[6.6–7.7] vs 7.6 [7.2–8.1], p = 0.038). Differences in the ini-
tial NIHSS score by TOAST classification showed a similar
pattern as observed in patients who were not treated with
thrombolytic therapy. (Additional file 1: Table S6).
Secondary outcome
A good functional outcome of mRS 0–2 at discharge
was achieved in 655 patients (68.0 %) among pre-stroke
statin users and 4395 patients (59.6 %) among non-
users, representing an absolute difference of 8.4 % (un-
adjusted OR, 1.44; 95%CI, 1.24–1.66; p < 0.001) and an
NNT of 11.9. The difference remained significant after
adjusting for covariates including the initial NIHSS score
and statin use during hospitalization (adjusted OR, 1.55;
95 % CI, 1.25–1.92; p < 0.001) (Table 3). Fig. 2 shows the
distribution of discharge mRS outcomes of the two
groups before and after PS analysis. In an unadjusted
analysis, pre-stroke statin use favorably shifted the distri-
bution of mRS outcomes (Cochran-Mantel-Haenszel
test, p < 0.001). After adjusting for covariates, the associ-
ation of statin use with the favorable shift in the mRS
outcomes remained significant (adjusted OR, 1.30;
95%CI, 1.12–1.51; p = 0.001) (Table 3).
To examine the effect of statin initiation during
hospitalization among patients without pre-stroke statin
use, we compared discharge mRS between statin users
(n = 5428) and statin non-users (n = 1892) during
hospitalization. In unadjusted analyses, statin initiation
during hospitalization was associated with better dis-
charge mRS outcome in both binary and ordinal ana-
lyses. After adjusting covariates including initial NIHSS
score, statin initiation was not associated with better
mRS outcome in binary analysis (OR, 1.08; 95 % CI,
0.94–1.24; p = 0.31), but the association was significant
in ordinal analysis (OR, 1.26; 95 % CI, 1.14–1.40; p < 0.001)
(Additional file 1: Table S7).
In the PS-matched cohort, pre-stroke statin use was
associated with favorable mRS outcome in both binary
(adjusted OR [95 % CI], 1.47 [1.16–1.88]; p = 0.002) and
ordinal analyses (adjusted OR [95 % CI], 1.26 [1.06–1.50];
p = 0.008). In the PS-stratification cohort, which served as
sensitivity analysis, pre-stroke statin use was also signifi-
cantly associated with good functional outcome as well as
a favorable shift in the mRS outcomes (Table 4).
Among stroke subtypes, multivariable analyses showed
that the association of pre-stroke statin use with achieving
a mRS 0–2 outcome at discharge was significant in patients
with CE, whereas the association of pre-stroke statin use
with a favorable shifting on the discharge mRS score was
significant in those with LAA (Additional file 1: Table S8).
When analyzing data of patients treated with thrombo-
lytic therapy, pre-stroke statin use was not associated with
an improvement of discharge mRS outcomes on shift
analysis (Cochran-Mantel-Haenszel test, p = 0.461) as well
as on dichotomized analysis (unadjusted OR, 1.03; 95 %
CI, 0.75–1.41; p = 0.857). For 9916 patients, including
non-thrombolysed and thrombolysed patients, pre-stroke
statin was associated with a good outcome of mRS 0–2 at
discharge (adjusted OR, 1.41; 95%CI, 1.16–1.71; p =
0.0004) as well as a favorable shifting on the discharge
mRS (adjusted OR, 1.22; 95%CI, 1.06–1.40; p = 0.0063)
after adjustment for covariates (Additional file 1: Table S9).
To investigate the effect of prestroke statin by onset to ar-
rival time, we performed stratified analysis using median
onset to arrival (7.6 h). For initial stroke severity, the pre-
stroke statin effect was significant in patients arriving
within 7.6 h, but not in patients arriving after 7.6 h, and the
interaction was significant (Additional file 1: Table S10).
However, for functional outcome, there was no significant
interaction for dichotomized mRS analyses and shift
analyses. In the mRS 0–2 dichotomized analysis, the
prestroke statin effect was significant irrespective of on-
set to arrival time. In the shift analysis, the effect was
significant in patients arriving within 7.6 h, but showed
a non-significant trend in those arriving after 7.6 h
(Additional file 1: Table S11).
Discussion
This study shows that pre-stroke statin use was associ-
ated with lesser stroke severity at presentation. The
magnitude of the statin benefit on initial stroke severity
was relatively small: a decrease of 0.8 points of the
NIHSS score for the unadjusted analysis and a decrease
of 0.6 points for the adjusted and PS analyses. However,
the small decrease in the NIHSS score might be clinic-
ally meaningful because a 1-point decrease in the NIHSS
score was significantly associated with reduction of
hospitalization, the need for rehabilitation or a long-
term nursing facility [30, 31].
Most of the earlier studies have failed to detect the
benefit of pre-stroke statin use on initial stroke severity
[2, 10–14, 16–20, 23]. However, except for two studies
[16, 19], they had a small sample size of less than 1000
and accordingly were not adequately powered to detect
the pre-stroke statin effect on initial stroke severity.
Only two studies have demonstrated the beneficial effect
of pre-stroke statin on initial stroke severity [15, 21].
Both studies showed that pre-stroke statin was inde-
pendently associated with a higher probability of mild
stroke severity as defined by the NIHSS score of 0–5,
but they did not provide the pre-stroke statin effect on
the overall stroke severity after adjusting for covariates.
When comparing the NIHSS score between two groups,
the analysis of the overall NIHSS score distribution is
preferred to a dichotomized analysis because of 1)
retaining all stroke severity information captured by the
NIHSS score, 2) being free from a cut-off point bias
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Table 3 Multivariable binary and ordinal logistic regression analyses for mRS outcome for unmatched cohort
Binary logistic regressiona Ordinal logistic regressionb
OR 95 % CI P-value OR 95 % CI P-value
Demographic
Age, years 0.98 (0.97–0.98) <0.001 0.98 (0.98–0.99) <0.001
Sex, male 1.20 (1.04–1.38) 0.012 1.08 (0.97–1.20) 0.157
Pre-stroke mRS
1 Ref Ref Ref
0 1.31 (1.06–1.63) 0.012 1.54 (1.31–1.81) <0.001
BMI 1.00 (0.99–1.02) 0.65 1.00 (0.99–1.01) 0.64
Risk factors
Hypertension 1.03 (0.91–1.18) 0.63 1.01 (0.92–1.11) 0.87
DM 0.79 (0.70–0.88) 0 < .001 0.79 (0.73–0.86) <0.001
Hyperlipidemia 0.86 (0.75–0.98) 0.024 0.94 (0.85–1.04) 0.20
Smoking 0.93 (0.82–1.07) 0.32 1.04 (0.94–1.14) 0.48
Atrial fibrillation 1.27 (1.01–1.61) 0.046 1.11 (0.94–1.14) 0.24
History of stroke 0.99 (0.85–1.16) 0.90 0.97 (0.86–1.09) 0.58
History of CAD 0.79 (0.61–1.02) 0.068 0.88 (0.73–1.06) 0.178
Lab
DBP, (unit 10 mmHg) 0.94 (0.91–0.98) 0.002 0.95 (0.92–0.97) <0.001
Hemoglobin 1.04 (1.01–1.08) 0.023 1.03 (1.01–1.06) 0.015
Total cholesterol, (unit 10 mg/ dL) 0.95 (0.93–0.98) <0.001 0.96 (0.94–0.98) <0.001
LDL cholesterol, (unit 10 mg/ dL) 1.05 (1.01–1.08) 0.005 1.03 (1.00–1.05) 0.022
Stroke characteristics
Initial NIHSS score 0.76 (0.74–0.77) <0.001 0.76 (0.75–0.76) <0.001
Onset to arrival time 1.00 (0.99–1.00) 0.0719 0.99 (0.99–1.00) <0.001
Stroke subtype
Large artery atherosclerosis Ref Ref Ref
Small vessel occlusion 1.10 (0.87–1.39) 0.42 1.06 (0.90–1.26) 0.50
Cardioembolism 1.42 (1.21–1.67) <0.001 1.13 (1.01–1.27) 0.035
Others 1.14 (0.97–1.33) 0.120 1.08 (0.96–1.21) 0.20
Pre-stroke medication
Antiplatelet 0.97 (0.87–1.13) 0.72 0.95 (085–1.06) 0.35
Anticoagulant 0.98 (0.72–1.33) 0.888 1.03 (0.83–1.27) 0.81
ARB or ACEI 1.11 (0.95–1.29) 0.19 1.02 (0.92–1.15) 0.67
Beta-blocker 1.40 (1.12–1.75) 0.003 1.26 (1.08–1.48) 0.003
Diuretics 1.02 (0.83–1.25) 0.86 0.97 (0.84–1.13) 0.73
Calcium channel blocker 0.92 (0.79–1.08) 0.31 1.02 (0.91–1.15) 0.71
Statin use during hospitalization 1.09 (0.95–1.25) 0.22 1.26 (1.14–1.39) <0.001
SYSO 0.81 (0.71–0.91) 0.001 0.81 (0.74–0.89) <0.001
Pre-stroke statin use 1.55 (1.25–1.92) <0.001 1.30 (1.12–1.51) 0.001
mRS Modified Rankin scale, BMI Body mass index, DM Diabetes mellitus, DBP Diastolic blood pressure, CAD Coronary artery disease, NIHSS National Institutes of
Health Stroke Scale, ARB Angiotensin-receptor blocker, ACEI Angiotensin converting enzyme inhibitor, SYSO Symptomatic stenosis or occlusion
aDependent variable: mRS 0 to 2 versus 3 to 6
bDependent variable: six levels by collapsing mRS 5 and mRS 6 into a single level
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which is frequently observed in dichotomized analyses,
and 3) better detecting a therapeutic effect that is mild
to modest. In addition, of the two studies, one study spe-
cifically analyzed the statin effect [21], but the other
study assessed the effect of lipid-lowering therapy in-
cluding statins and other lipid-lowering drugs [15]. In
our study, the impact of pre-stroke statin on the overall
stroke severity was more convincingly demonstrated by
ensuring a substantial statistical power and enabling an
extensive covariate adjustment as well as PS analyses.
In accord with earlier observational studies, we found
that pre-stroke statin use was associated with good func-
tional outcome at discharge. Compared to non-users, sta-
tin users had a 1.55-fold increased odds of achieving a
good outcome (mRS 0–2) and a 1.29-fold increased odds
of a favorable single level transition on the mRS disability
score after adjustment for covariates including the initial
NIHSS score and statin use during hospitalization. The in-
ternal validity of our findings is supported by the consist-
ent magnitudes of the associations between multivariable
Table 4 Multivariable binary and ordinal logistic regression analyses for mRS outcome for unmatched and PS-matched cohorts
Binary outcomea Ordinal outcomeb
OR 95 % CI p-value OR 95 % CI p-value
Crude analysis,
unmatched cohort
1.44 (1.25–1.66) <0.001 1.37 (1.21–1.54) <0.001
Multivariable analysisc,
unmatched cohort
1.55 (1.25–1.92) <0.001 1.29 (1.12–1.51) 0.001
PS- matched
analysisd, e
1.47 (1.16–1.88) 0.002 1.26 (1.06–1.50) 0.008
PS-stratification,
decilesf
1.57 (1.25–1.96) <0.001 1.31 (1.11–1.54) 0.001
Odd ratio for statin use prior to stroke
aDependent variable: mRS 0 to 2 versus 3 to 6
bDependent variable: six mRS levels by collapsing mRS 5 and mRS 6 into a single level
cAdjusted for age, sex, body mass index, diastolic blood pressure, hemoglobin, total cholesterol, LDL cholesterol, pre-stroke modified Rankin scale score, history of
hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, history of stroke, history of coronary artery disease, smoking, prior medication of any antiplatelet,
anticoagulant, angiotensin receptor blocker or angiotensin converting enzyme inhibitor, beta-blocker, diuretics, calcium-channel blocker, TOAST classification, on-
set to arrival time, statin use during hospitalization, SYSO, and initial NIHSS score
dPS-matched sample included 618 pairs with one-to-n (n ranged from one to four) matching: 618statin users and 1585 non-users
eAdjusted for history of stroke, hyperlipidemia, total cholesterol, LDL cholesterol, prior medication of any antiplatelet, ARB + ACEI, statin use during hospitalization,
SYSO, and initial NIHSS score
fAdjusted for statin use during hospitalization, SYSO, and initial NIHSS score
Fig. 2 Distribution of modified Rankin Scale (mRS) score at discharge (a. unmatched, b. PS-matched)
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analyses and PS analyses for both of the dichotomized and
shift analyses (Table 4). The external validity is supported
by the comparable magnitude of benefit reported in a re-
cent meta-analysis that pooled 9 studies of 17,512 patients
and assessed mRS 0–2 at discharge or at 30 days: the odds
ratio (95 % CI) of pre-stroke statin use for achieving a
mRS 0–2 outcome was 1.55 (1.25–1.92) in our study ver-
sus 1.64 (1.14–2.36) in the meta-analysis [22]. In addition,
the favorable shift on the mRS score observed in the
current study is generally comparable to the results of an
exploratory analysis of the SPARCL trial, which analyzed
the 90-day mRS outcome of 454 patients experiencing re-
current ischemic stroke during the trial (197 patients ran-
domized to high dose atorvastatin versus 257 to placebo)
[24]. In the absence of randomized trials specifically de-
signed to test the effect of pre-stroke statin on stroke out-
come, data from such randomized trial settings are likely
to better ensure baseline balances of two comparative
groups than observational studies. However, the SPARCL
exploratory analysis was not adequately powered to detect
a favorable mRS shift. In addition, that study was not able
to adjust the initial stroke severity of the recurrent ische-
mic stroke because of the unavailability of the data. In
contrast, our study with a larger sample size that assessed
the initial NIHSS score for each patient was able to ob-
serve a favorable mRS shift and to adjust for the initial
stroke severity.
Animal experiments have shown that pretreatment
with statin have neuroprotective actions of enhancing
angiogenesis, reduction of clot formation or facilitation
of clot lysis, and upregulation of endothelial nitric oxide
synthase [4–6, 9], and statin treatment after stroke had
neurorestorative actions of promoting neurogenesis, syn-
aptogenesis, and angiogenesis [8]. Thereby, pre-stroke
statin use might affect not only initial stroke severity but
also early stroke recovery. However, no prior human
stroke study has demonstrated both of these effects sim-
ultaneously. Several studies showed better functional
outcome but failed to show lesser initial stroke severity
in patients with pre-stroke statin use [10–12, 16, 18, 19].
On the contrary, in one study, pre-stroke statin was as-
sociated with lesser stroke severity but not with better
functional outcome [21]. In another study, pre-stroke
lipid-lowering therapy of statin or fibrate was independ-
ently associated with both mild stroke severity and early
good functional outcome. However, in an additional
multivariable model including initial stroke severity, the
association of pre-stroke lipid-lowering therapy and
good functional outcome was not significant. Therefore,
the better functional outcome might be attributed to the
lesser stroke severity rather than early post-stroke recov-
ery [15]. In contrast, we found that pre-stroke statin use
was associated with both lesser stroke severity and better
functional outcome even after adjusting for initial stroke
severity, suggesting that pre-stroke statin in human
strokes might lead to not only lesser stroke severity but
also early stroke recovery.
Previous studies have shown that pretreatment with
statin for statin-naïve patients or reloading of high dose
statin reduced myocardial infarction in patients under-
going percutaneous coronary intervention for stable an-
gina or acute coronary syndrome [32–34], and current
guidelines state that high-dose statin therapy before per-
cutaneous coronary intervention is reasonable [35, 36].
In contrast, stroke guidelines do not clearly state whether
statins should be initiated immediately or delayed during
the acute period of ischemic stroke. In a small randomized
trial, statin withdrawal for a brief period of 3 days in acute
ischemic stroke patients who were already taking statins
was associated with increased risk of death or dependency
at 3 months [37]. On the basis of the results, the current
guidelines recommend that continuation of statin therapy
during the acute period of ischemic stroke is reasonable
for patients already taking statins at the time of ischemic
stroke onset [38]. In this study, statin withdrawal among
pre-stroke statin users had a trend of worse mRS out-
come, but the association was not statistically significant.
The insufficient statistical power due to a small sample
size might in part account for the negative association. In
contrast, among pre-stroke statin non-users, statin initi-
ation during hospitalization was significantly associated
with a favorable mRS shift. Our results along with other
studies suggest that 1) for patients at high risk of cardio-
vascular disease, statins should be recommended to ameli-
orate the disability from brain or heart attack as well as to
prevent these events; and 2) during the acute stage of is-
chemic stroke, continuation of statin therapy for patients
on chronic statin therapy and immediate statin initiation
for statin-naïve patients might be beneficial to improve
functional outcome after stroke.
Statin effect on stroke severity and functional outcome
might differ depending on ischemic stroke subtypes. In
earlier studies, pre-stroke statin was not associated with
mild stroke severity in all stroke subtypes [16], whereas
it was associated with better functional outcome in
strokes due to SVO and LAA [16, 17]. In the current
study, for LAA and SVO, the association of pre-stroke
statin with lesser stroke severity was significant in un-
adjusted analyses but showed trends without statistical
significance in adjusted analyses. For early functional
outcome, adjusted analyses showed more mRS 0–2 out-
comes in CE and favorable mRS shifts in LAA with pre-
stroke statin use. Limited statistical power due to small
to modest sample sizes for individual stroke subtypes in
the current and previous studies limits the interpretation
of the inconsistent findings.
Our study has several limitations. This was an observa-
tional study, which could not control unmeasured
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confounders. In addition, data were prospectively collected
in but retrospectively abstracted from a registry database
and thereby might not be as accurate as those from clin-
ical trials. However, to ensure the accuracy of data, we
used a pre-defined standardized coding system and data
quality was audited regularly. The effect on stroke out-
come might differ across statin types, doses, and dura-
tions, as suggested in experimental studies [6, 39]. Since
our registry did not capture relevant data, this study was
not able to analyze these effects. Although a recent study
did not find a dose-dependent effect of pre-stroke statin
on initial stroke severity, the results might be attributed to
lack of statistical power [21]. We assessed mRS outcomes
at discharge, but could not analyze the 90-day mRS out-
come disability, which is recommended as a preferred
functional outcome measure in acute stroke research [40,
41]. However, an earlier study analyzing the NINDS-TPA
(National Institute of Neurological Disorders and Stroke
rt-PA) trial database showed that mRS at day 7/10 strongly
correlated with the 90-day mRS [42]. Finally, we could not
find a significant association between prestroke statin and
functional outcome in patients treated with thrombolytic
therapy due to small sample size. Future clinical trials
should validate the effect of prestroke statin in patients
with acute stroke.
Conclusions
The present study suggests that pre-stroke statin use
might be associated with milder stroke severity at pres-
entation and better early recovery in patients with acute
ischemic stroke. Our findings need to be replicated in
other well-designed studies.
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